Top Biotech Takeover Targets 2020

Trending; Sectors. Published: 17:02 EDT, 11 January 2020. SMITHFIELD, R. Vertex Pharmaceuticals (NASDAQ: VRTX) has also experienced a surge, up 75% this year. This year will likely see just as much activity but smaller price points, PwC. COPYRIGHT ©2005–2020 ETF TRENDS. Live customer service right here in the United States in case you ever have a question about your subscription. Top Biotech Takeover Targets for 2020: Are These The Best Stocks to Buy Now? More than 25 merger and acquisition activities have been executed in the biotech industry in 2019. Gamida stock has a resounding “yes” on Wall Street. The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm at OrbiMed Capital. 1 billion in Q1 of 2019. 3 Potential Biotech Buyout Targets in the Second Quarter Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns. Many of them can stand on their own but look even better as potential buyout targets. The article was written by Motek Moyen Research Seeking Alpha's #1 Writer on Long Ideas and #2 in Technology - Senior Analyst at I Know First. That makes these the biggest biotech takeover targets. What’s exciting about that is that the first company to market with an off-the-shelf T-cell immunotherapy will be an enticing buyout candidate, and both Gilead and. Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts. for $73 a share in cash, or $5. Esports & Gaming; Cannabis, CBD & Hemp; Technology; Biotech & Healthcare. After biotech stock Relypsa was bought out last week for a 60% premium, the odds of M&A heating up in this sector increased dramatically. Innately Adaptive™ Oncolytics Biotech Inc. (WPRI) - The manufacturing facility vacated last fall by Alexion Pharmaceuticals is getting a new owner. A good buy for 2020. They remain optimistic about the prospects for the sector in 2020 due to high levels of innovation and a relaxed regulatory environment, while a continuation in merger and acquisition (M&A) activity would also likely provide further support for biotech shares. But, entering an election year, the industry appears at a crossroads, where excitement over clinical breakthroughs like gene therapy meets intensifying questions over how well the industry is upholding its social contract. Top Stocks; Trifecta Stocks; Home / Investing / Healthcare. The company is expected to report top-line data from tabelecleucel’s late-stage trials within the first half of this year, which sets up a possible regulatory filing by mid-2020. 01:21 PM ET. The only trick I know of to identify potential takeover targets is to look for biotech companies with large pharma partners. Six-month data from the open-label extension portion due 3Q 2020. New special situations reports on biotech stocks breaking out, before they break out. Kite Pharma, acquired last year by Gilead Sciences for $11. struggles to convince rival Syngenta AG to discuss a potential merger , the seed and agrochemical giant is also wooing U. Wednesday, April 22, 2020. Top Picks 2020: Myovant Sciences Ltd. SMITHFIELD, R. 981 million. These 6 biotech stocks are promising takeover targets MarketWatch. 67 shows a. As late as August 28, AlphaStreet included Sarepta as one of “four biotech stocks that are ideal takeover targets. Noxopharm’s US biotech subsidiary Nyrada IPO successfully raises $8. New innovation, demand for better care, and an aging baby boomer population are continuing to fuel a multi-year rally in the sector. REPORT: What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World! Seneca Biopharma (CUR). The company is expected to release top-line data from tabelecleucel's late-stage trials in the first half of this year, potentially setting the table for a regulatory filing in early to mid-2020. went in the 2020 NFL Draft article/3-Biotech-Companies-Ripe-for. Support: 888 leading cause of liver transplants by 2020. farmers, aiming to ease concerns about the proposed tie-up that could prompt regulatory challenges, reports. Wall Street expects health care to be one of the best sector in 2020. Here Is His Top Pick. engages in the acquisition, exploration, and development of mineral deposits. Why 4 Top Biotech Stocks May Be the Next Takeover Targets that mergers and acquisitions continue in the biotech space. Every time GEN has compiled a list of takeover targets, stretching back to the first one in 2013, BioMarin Pharmaceutical has been one of the companies mentioned. Plus, spot the right trade and you could make a fortune. And companies' interest in deepening their focus on a therapeutic area will continue to drive new deals this year. Phase 2 top-line data noted TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks - April 20, 2020. Louis company’s drive to expand and protect its technology made it a poster child for large-scale agriculture and a nemesis of. ALXN has been in the spotlight as a potential takeover target from the onset of 2019, after the mega-merger announcement of Bristol-Myers BMY and Celgene CELG. Best Biotech Stocks To Buy In 2020! - Duration: 6:47. Merck and Allergan have both reached out to the Big Biotech about a tie-up. The company’s principal properties include the Aurizona gold mine covering a total land package of approximately 2,000 square kilometers located in Maranhão State, Brazil; and. The SPDR S&P Biotech ETF fell 35% from its September peak. 1 billion in Q1 of 2019. 10% Merck MRK, -3. ” Seattle Genetics One is growing sales of its sole marketed drug Adcetris® (brentuximab vedotin) in the U. , ImClone Systems Inc. BioMarin shares pop on strong pivotal data for rare disease drug Analysts show why orphan drug development is going gangbusters Buzz: Big investors likely to back next wave of biotech buyouts. A new UK biotech, Azeria Therapeutics has started on a mission to develop breakthrough treatments for breast and prostate cancer, based around a new drug target known as FOXA1. This company has been in the takeover rumor mill for some time. And right now, Isaly is pounding the table on behalf of biotech. Acquisition rumors have swirled around specialty biotech BioMarin Pharmaceutical (NASDAQ: BMRN) for years now. Here are Mizuho's top nine biotech stocks to buy right now. The price target of $17. -based Shire plc (ADR) (NASDAQ:SHPG) for Baxalta Incorporated (NYSE:BXLT). Jim Cramer's Top Takeover Targets for 2019 Trade tensions with China and a weaker economy could lead to a scarce M&A market in 2019, but tech, media and consumer deals could still trickle out. The growth category has pushed ahead of value through much of the decade-long bull rally, and it continues to hold true in 2020, with the S&P 500 and S&P Small Cap 600 growth indices outshining. Vertex Pharmaceuticals (NASDAQ: VRTX) has also experienced a surge, up 75% this year. Insights and Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts. 76 per share in. A Biotech Takeover Target. Biotech CEOs Share Ideas for Coping With Coronavirus The Wall Street Journal 10:51 6-May-20 India to send nearly 1,000 tonnes of paracetamol raw material to Europe The Times of India 10:37 6-May-20 PCI Biotech: Notice of Annual General Meeting 2020 GlobeNewswire (Press Release) 10:07 6-May-20. With biotech stocks surging in the last part of 2019, next year is setting up to remain strong for the sector. Who is the Next Biotech Takeover Target? Dr. completes its spinoff of the company Aug. The company first took off in November after announcing interim data on the effects of iontophoretic delivery of its EGP-437 ophthalmic solution on patients with macular edema. The global green biotech industry will climb 68% by 2024 and reach $66. Robinson, Strategic Tech Investor • May 6, 2015 The following share-price jumps underscore just how much money there is to make in the merger and acquisition (M&A) market – if you know how to choose the right buyout targets, that is. Spectrum Pharmaceuticals (SPPI) neared a breakout Tuesday on reports that it could be among a number of biotech companies seeking pharmaceutical mergers. Novartis (NYSE: NVS) is planning to spend as much as $10 billion per year on acquisitions. Another possible takeover target Alteryx, which is on our Watch List, is a provider of a cloud-based, self-serve data prep and analytics platform. MOLECULIN BIOTECH, INC. REPORT: What Curing Cancer & HIV Could Mean for This Company, Its Investors & The World! Seneca Biopharma (CUR). with mid- to late-stage gene therapy pipelines could be takeover targets. and Canada, which during January–June 2019 zoomed 35% year-over-year, to $293. farmers, aiming to ease concerns about the proposed tie-up that could prompt regulatory challenges, reports. Biotech got destroyed in Fall of 2018. By Martin Baccardax. 5bn Share on Twitter (opens new window). Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. Top Shale Takeover Targets By Michael McDonald - Jun 30, 2015, More Top Reads From Oilprice. BioMarin is a biotech jewel committed to the development of medicines for hemophilia and orphan diseases. But of course, virtually every stock that makes a good takeover target, is a good investment too. Over the past three years, IONS has had three drugs approved, and, in the near term, five more approvals are likely. In 2020, price-to-earnings valuations may expand to correct the market discount. for $73 a share in cash, or $5. Lundin Mining Scoping Out Potential Junior Zinc Takeover Targets. Shopify (SHOP) Source: Jirapong Manustrong / Shutterstock. Location: San Diego, CA. However, they also grappled with more expensive medical. Thursday, May 02, 2019. Before Behind the Markets, Jovine launched Tycoon Publishing in 2004 and Lexington Capital Partners in 1996. 6%, to finish the regular session at 21. 7 billion all-cash purchase of AveXis Inc. iRobot is the best game in town in that space. 2017 was the first year since 2013 when Vertex , a biotech that targets cystic fibrosis, cancer, autoimmune diseases and more, broke even — and in 2019 it is likely to make $3. Takeover Target Monsanto Helped Shape Biotech Revolution St. Many of them can stand on their own but look even better as potential buyout targets. Takeover Targets makes the market a little easier for the average investor to handle. Shares have been falling since 2017 on. Takeover targets can deliver big upside if an offer comes through. Thursday, May 02, 2019. Biotech takeover targets. In this first edition, host Peter Strachan discusses all things gold with a panel of WA gold stocks likely to be on the radar of the majors. 3 Biotech ETFs Up 10% Or More Over The Last Month - MarketWatch Posted: May 7, 2020 at 5:54 pm Something's been brewing in the health care sector, the second-largest group in the S&P 500. Tulipmania has practically taken over the hepatitis C market, with Gilead Sciences. Vascepa (icosapent ethyl) is a. Biotech Cellectis in takeover talks with Pfizer US pharma company has approached French biotech for deal worth as much as €1. 7 billion, per Market Data Forecast. In a stunning move, a US cannabis multi-state operator has launched a takeover bid for Canadian licensed producer (LP) Aphria (NYSE:APHA,TSX:APHA). Overall, third quarter 2016 earnings …. com: One Biotech Stock For 2020. ALXN is down 22% from its all-time high of $141. 1 billion in cash and a 62% premium to the company's market price — said it plans to spend more on its cancer-related research. Hisfirm or clients may own or trade securities discussed in this column. Who is the Next Biotech Takeover Target? Dr. Biotech looked "as de-risked as it could be, in terms of exit options," said Jeffrey Tong, partner at US venture capital firm Third Rock Ventures, speaking in early February 2020. New special situations reports on biotech stocks breaking out, before they break out. Big biotech is about to go on a shopping spree to replenish their pipelines as many small cap biotechs are selling for lows not seen since 2011. As prices fall, investors should keep an eye on these seven companies. By Jamie Nimmo For The Financial Mail On Sunday. INCY has gained 43% year-to-date and trades around $91. Here are five stocks that are attractive and most likely to be takeout targets in 2019. Biogen (NASDAQ: BIIB) recently suffered a brutal stock market beating after its big Alzheimer's candidate failed to make a difference for patients with early signs of the disease. The company first took off in November after announcing interim data on the effects of iontophoretic delivery of its EGP-437 ophthalmic solution on patients with macular edema. Synergy Pharma Becomes an Attractive Takeover Target After Drug Wows in Phase III Study Analysts , CIC/IBS , FDA/Regulatory , Gastrointestinal , M&A , R&D , Stocks Will good news and a stock surge mean Synergy Pharmaceuticals is soon to be a target for acquisition?. Trending; Sectors. Shopify (SHOP) Source: Jirapong Manustrong / Shutterstock. PLC ADS AMRN Stock Message Board: AF's Biotech 2020 preview: Takeover targets, notable drug. 7 billion all-cash purchase of AveXis Inc. Keep an eye out for Allergan, Arena Pharmaceuticals, and Bristol-Myers Squibb. It is therefore not surprising that a lot of rumors circulate in the news about the top biotech takeover candidates and potential buyout targets in the field of biotechnology. April 26, 2019; Crispr's stock is likely to skyrocket and such a success would certainly put the company's name at the top of the buyout rumor stack. ” Seattle Genetics One is growing sales of its sole marketed drug Adcetris® (brentuximab vedotin) in the U. On top of this, IONS has more than $2 billion in cash and equivalents on the balance sheet. to reflect the probability of being acquired by a large pharmaceutical company. ( BMRN ), Bluebird Bio Inc. Next Biotech Takeout Targets, NewLink Genetics Pulls 2020 Profit Guidance. Here are the top 5 takeover targets identified by Lone Pine Capital and snapped up by at least 38 hedge funds: Bonus Biotech Stock Pick: All text and design is copyright ©2020 Koala Guide. 4 Biotech Penny Stocks That Are Up Over 100% So Far in 2020 So far in March, stock markets have experienced massive losses as the coronavirus outbreak continues to wreak havoc on the global economy. On top of this, IONS has more than $2 billion in cash and equivalents on the balance sheet. 01:21 PM ET. BMS is paying a 54% premium to Celgene’s closing stock price on January 2. Alex­ion is al­so on every­one's top-5 list of takeover tar­gets. Six-month data from the open-label extension portion due 3Q 2020. In this first edition, host Peter Strachan discusses all things gold with a panel of WA gold stocks likely to be on the radar of the majors. SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5. Vertex Pharmaceuticals (NASDAQ: VRTX) has also experienced a surge, up 75% this year. Biotech Breakouts and Takeover Targets. ( BMRN ), Bluebird Bio Inc. An­a­lysts' top 10 biotech takeover tar­gets are con­cen­trat­ed in two key ar­eas. (BMRN) BioMarin is almost every analyst's favorite takeover. Notably, a slowdown in mature products due to the increasing competition and rise of biosimilars have forced most pharma/biotech behemoths to target lucrative buyouts in this space to bolster their pipelines. Geron Corporation (NASDAQ:GERN). Wednesday, April 22, 2020. In addition to the stocks discussed above, would you like to know about our 10 top tickers for the entirety of 2020? These 10 are painstakingly hand-picked from over 4,000 companies covered by the Zacks Rank. could be acquired by a competitor in the agricultural biotech industry after Pharmacia Corp. 8 Takeout targets to watch in 2018 Any company that can get its gene therapy technology to work will stand out as a takeover target. The global blue biotech industry is set to soar 86% by 2024 and reach $6. Be a Bull in This Biotech Breakout. Diabetes is another hot niche of the biotech arena, but that's. Incyte was among 10 biopharmas cited as takeover targets in a Bloomberg News survey of 20 M&A/event-driven trading desks, analysts, and fund managers—as well as one of 10 companies on the "Biotech Buyout Watchlist for 2019" published by stock website "PrecisionTrade365. Biotech CEOs Share Ideas for Coping With Coronavirus The Wall Street Journal 10:51 6-May-20 India to send nearly 1,000 tonnes of paracetamol raw material to Europe The Times of India 10:37 6-May-20 PCI Biotech: Notice of Annual General Meeting 2020 GlobeNewswire (Press Release) 10:07 6-May-20. Check out our top picks for best share dealing brokers. HTTP://tiny. Biotech columnist Adam Feuerstein answers readers' questions about health care companies. John Dorfman, chairman of Thunderstorm Capital in Boston, is acolumnist for Bloomberg News. 2020 10:11 AM EDT. Shares of Immunomedics rise 1% on FDA approval of breast-cancer drug MarketWatch. Morgan Stanley has just released a very intriguing report highlighting 15 stocks that are most likely to be bought in 2018. Here are the top 5 takeover targets identified by Lone Pine Capital and snapped up by at least 38 hedge funds: Bonus Biotech Stock Pick: All text and design is copyright ©2020 Koala Guide. Mergers really haven't been a factor in the market recently, unless you focus on the health care sector. Wall Street analysts anticipate about $1 billion in peak annual sales, and it will certainly attract takeover speculation. This company was rumored to be a takeover target for Amgen for over a year, and the stock plunged over 5% when earlier this week Amgen announced the deal with Celgene. Biopharma management teams like to look busy during a time of crisis, plus bulking up helps prevent the loss of their jobs due to a takeover. Industry pros think these ETF themes will take hold in 2020. 5 Top Drug/Biotech Merger & Acquisition Targets for 2019 - December 10, 2018 - Zacks. April 23, 2020 - Your 2 Top Profit Opportunities in 2020 April 23, 2020 - Apple Stock: Buy, Sell, or Hold? 2 Best Biotech BUYOUT Plays. 2) Auxilium Pharma, $1. Nascent Biotech: This Cancer Research Microcap Has A Drug in Testing with Indications for Use Against COVID-19 Green Growth Brands Targets Aphria in Takeover Bid. struggles to convince rival Syngenta AG to discuss a potential merger , the seed and agrochemical giant is also wooing U. 981 million. May 1, 2020. ALXN has been in the spotlight as a potential takeover target from the onset of 2019, after the mega-merger announcement of Bristol-Myers BMY and Celgene CELG. Summary: On Semiconductor is the no. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Brian Kelly, Chris Verrone and Steve Grasso. Top 10 M&A targets in 2020 We have a look at the top #potential takeover targets for 2020 and explain how investors and traders can capitalise. In each of its last two quarters, Alteryx has. PharmaTEC and PROCESS summarise the largest deals in the history of the industry for you. The price tag of 14 deals was higher than $1 billion. The list of biotech companies valued at more than €1B grew, and we saw some big acquisitions, including those of. The only trick I know of to identify potential takeover targets is to look for biotech companies with large pharma partners. Biotech Breakouts and Takeover Targets. This company has been in the takeover rumor mill for some time. Fly Fri Sep 11, 2015 8:33am EST 9 Comments In light of GILD raising $10 billion in a convertible bond offering, I did a little digging into who might be an attractive acquisition target, not only for them, but any major pharma. ALSO READ: 2017 Bull-Bear Case for Health Care: J&J, Merck, Pfizer, UnitedHealth. FACTBOX-Top biotech takeout targets of 2010 -Morningstar 1 Min Read NEW YORK, March 9 (Reuters) - Here are the biotechnology companies most likely to be bought in 2010, according to analysts at. ( BLUE ), Acadia Pharmaceuticals Inc. Todd Onyx is also a top-10 holding in that ETF. ( MYOV ) offers a new drug “pipeline in a pill”, asserts biotech expert Jay Silverman , contributing editor to Medical Technology Stock Letter. Live customer service right here in the United States in case you ever have a question about your subscription. Novartis (NYSE: NVS) is planning to spend as much as $10 billion per year on acquisitions. The FDA decision on Pemigatinib is expected by May 30, 2020. 8 billion, both in January. Hisfirm or clients may own or trade securities discussed in this column. January 14, 2020. Takeover Targets: Anaconda Mining and two steps to success Peter Clausi | February 18, 2015 | 6 Comments Earlier in this series we looked at Integra Gold Corp, which became a takeover target when the market failed to price in meaningful information already in the public domain. On the stock market today, Spectrum rocketed 14. Biogen-Idec (NASDAQ:BIIB) and Allegan (NYSE:AGN) were up 5% and 6%, respectively. The price target of $17. My 2 newest include: 2 Biotech Takeover Targets Under $7 and Forget Heart Disease: 1 Stock to Enjoy a Long, Healthy, Prosperous Retirement. 11:43 AM ET. (MYOV) January 22, 2020 Myovant Sciences Ltd. 86, recorded on April 10, 2019, and trades around $110. German biotech company BioNTech, which has approval for human trials of potential coronavirus vaccines, has lately been contacted by industry players but is not interested in a takeover, a newspaper reported on Saturday. com - Apr 07, 2020 16 Oil Tumbles 9% on Doubts Whether Any Producer Cuts Will Be Enough By Investing. A Biotech Takeover Target. (BMRN) BioMarin is almost every analyst's favorite takeover. 10 Companies That May Be on Warren Buffett's Takeover List A long-established cottage industry within the investment community is trying to anticipate Warren Buffett's next moves and to profit. (Also see "Medigene's bluebird Deal Validates TCR Technology And Immune-Oncology Strategy" - Scrip, 4 Oct, 2016. agreeing to buy Allergan PLC’s generic drugs business for US$40. This company is fighting cancer by "sticking" its targets, just like a missile fired from an F-35 fighter jet would lock in on an enemy jet. The biggest deals have been Sanofi's acquisition of Bioverativ for about $11. “From drastically improving diagnostics and treatment decisions, to accelerating patient recruitment for clinical trials, the combination of AI and Big Data is changing. Myovant Sciences: One of the Takeover Targets in Biotech Industry for 2020 More than 25 mergers and acquisitions have been executed in biotech industry in 2019. Departures Capital 591 views. Gilead's other two NASH drugs, GS-9674 and GS-0976, are in phase 2 clinical studies. SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5. Incyte was among 10 biopharmas cited as takeover targets in a Bloomberg News survey of 20 M&A/event-driven trading desks, analysts, and fund managers—as well as one of 10 companies on the "Biotech Buyout Watchlist for 2019" published by stock website "PrecisionTrade365. Location: San Diego, CA. The rally was sparked by yet another mega-deal in the pharma space, with Teva Pharmaceutical Industries Ltd. Among the biotechs thought by some savvy investors to be a near-term takeover target is. BioMarin Pharmaceutical Inc. Opko Health Inc. " Cantor Fitzgerald- Puma Biotechnology, overweight rating "We reiterate our Overweight rating and $57 Price Target. PLC ADS AMRN Stock Message Board: AF's Biotech 2020 preview: Takeover targets, notable drug. Given the risk inherent in the sector it is important to pick stocks wisely- for example, by choosing stocks with recent buy recommendations from top analysts. that may be logical acquisition targets next year for big dug/biotech companies like Gilead, Amgen, Pfizer, Merck, Johnson & Johnson. Vascepa (icosapent ethyl) is a. and Humana, both in the process of being swallowed up by larger competitors, each reported higher third-quarter earnings Friday. Biotech Stocks To Watch for 2020 Seattle Genetics. BioMarin has already been the target of takeover speculation. an object or area toward which something is directed. Shanghai Junshi Biosciences, which has 13 biologics in development, hopes to raise $414 million in its bid to go public, reports Reuters. Some analysts predict that the market for treatments of nonalcoholic steatohepatitis (NASH) could be between $20 billion and $35 billion. This Biotech Stock Is Nearing A Breakout On Takeover Rumors. As 2018 drew to a close, we had a look at how many companies had been doing and what their prospects were for the new year. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Brian Kelly, Chris Verrone and Steve Grasso. FIZZ stock is one of the most compelling takeover opportunities for 2018 and beyond. farmers, aiming to ease concerns about the proposed tie-up that could prompt regulatory challenges, reports. And there's. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological. But, entering an election year, the industry appears at a crossroads, where excitement over clinical breakthroughs like gene therapy meets intensifying questions over how well the industry is upholding its social contract. Amgen (NYSE: AMGN) is supposedly near a deal to buy Alexion Pharmaceuticals (NASDAQ: ALXN) at a whopping 74 percent premium. April 28, 2020 - This Chip Stock Pays a Nice Dividend, but Should You Buy? April 27, 2020 - Better Buy: Amazon vs. 1 billion in cash and a 62% premium to the company's market price — said it plans to spend more on its cancer-related research. 00 or better Sell Target – TradersPro Sell Signal Equinox Gold Corp. ) The expanded deal and complementary tech make Medigene a logical acquisition target for bluebird. to reflect the. HTTP://tiny. 3 Potential Takeover Targets For the High-Risk Portion of Your Portfolio by Michael A. Projections begin in 2019. Learn about LXRX with our data and independent analysis including price, star rating, valuation, dividends, and financials. 94% , AMGN, -3. OptionsXpress was an obscure online trading company once upon a time. and Genzyme Corp. Another possible takeover target Alteryx, which is on our Watch List, is a provider of a cloud-based, self-serve data prep and analytics platform. 4-per-cent gain on Monday and its wide outperformance versus large-cap biotech peers have investors thinking it may be a takeover target. The article was written by Motek Moyen Research Seeking Alpha's #1 Writer on Long Ideas and #2 in Technology - Senior Analyst at I Know First. Put an increasingly prevalent liver disease high on the list. 5 Top Drug/Biotech Merger & Acquisition Targets for 2019. 7 'A'-Rated Stocks to Buy Under $10. Biotech That Doubled on Covid-19 Frenzy Readies New Flu Vaccine By. Biotechnology, a sub-sector in the health care sector was really hot in 2019. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological. The FDA decision on Pemigatinib is expected by May 30, 2020. Phase 2 top-line data noted TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks - April 20, 2020. A Biotech Takeover Target. Industry watchers have been predicting for months that buyers would come for Biogen--and now, one report says, they have. Given the risk inherent in the sector it is important to pick stocks wisely- and choosing stocks recommended by top analysts is one way of pinpointing top biotech stocks. A roundup of STAT's top stories of the day in science and medicine. Wall Street analysts anticipate about $1 billion in peak annual sales, and it will certainly attract takeover speculation. with mid- to late-stage gene therapy pipelines could be takeover targets. Notably, a slowdown in mature products due to the increasing competition and rise of biosimilars have forced most pharma/biotech behemoths to target lucrative buyouts in this space to bolster their pipelines. PLC ADS AMRN Stock Message Board: AF's Biotech 2020 preview: Takeover targets, notable drug. “From drastically improving diagnostics and treatment decisions, to accelerating patient recruitment for clinical trials, the combination of AI and Big Data is changing. is developing pelareorep, a safe and well-tolerated intravenously delivered immuno-oncolytic virus (IOV) that kills cancer through a unique mechanism of action with two components, selective tumor lysis and activation of the innate and adaptive immune systems, creating an inflamed phenotype to treat a variety of solid tumors and hematological. Biotechnology, a sub-sector in the health care sector was really hot in 2019. If Biogen follows the standard industry handbook, management will acquire a medium-sized. As late as August 28, AlphaStreet included Sarepta as one of “four biotech stocks that are ideal takeover targets. The company owns the top-selling cystic fibrosis (CF) drug, Orkambi. 7 'A'-Rated Stocks to Buy Under $10. Biotech CEOs Share Ideas for Coping With Coronavirus The Wall Street Journal 10:51 6-May-20 India to send nearly 1,000 tonnes of paracetamol raw material to Europe The Times of India 10:37 6-May-20 PCI Biotech: Notice of Annual General Meeting 2020 GlobeNewswire (Press Release) 10:07 6-May-20. Today we've got a teaser pitch from Dylan Jovine's new service, Takeover Targets, which he says is "half price" for charter subscribers (that would be $997/year, and unlike many higher-end newsletters they say they do offer refunds for 30 days)… and, as you might imagine, the service is all about identifying companies that might be […]. 11:43 AM ET. Porges says Biogen will likely have to wait until 2020 to see renewed takeover interest. However, one news outlet went on to report that one of the largest biotech stocks in the market is getting close to finalizing a major deal. Alexion Pharmaceuticals is a lesson in biotech investing. Who is the Next Biotech Takeover Target? Dr. The global green biotech industry will climb 68% by 2024 and reach $66. INCY has gained 43% year-to-date and trades around $91. M&A activity in the global biotech sector remains strong heading into 2020. Biotech Stocks To Watch for 2020 Seattle Genetics. By Jamie Nimmo For The Financial Mail On Sunday. This revelation should come as no surprise to many of our regular subscribers. Gamida stock has a resounding “yes” on Wall Street. Next Biotech Takeout Targets, NewLink Genetics Pulls 2020 Profit Guidance. Four years ago Endocyte was the laughing stock of biotech. 11:43 AM ET. Mergers and acquisitions have lit up biotech stocks, and the hot pace shows no sign of slowing in 2020. 4 biotech stocks that are ideal takeover targets August 28, 2019 April 8, 2020 Speculation plays a big role when investing in biotech stocks, hence making them highly volatile. Surprising clinical successes played a role in the rebound, but more consequential was a spate of deals that emphasized biotech's upside. Industry watchers have been predicting for months that buyers would come for Biogen--and now, one report says, they have. (BMRN) BioMarin is almost every analyst's favorite takeover. Top 10 M&A targets in 2020 We have a look at the top #potential takeover targets for 2020 and explain how investors and traders can capitalise. Estimated sales growth. By Simon Johnson STOCKHOLM (Reuters) - Sweden plans to tighten its rules to enable the government to block takeovers of important firms by foreign companies amid increasing concerns over the threat to national security from China and Russia. Spectrum Pharmaceuticals (SPPI) neared a breakout Tuesday on reports that it could be among a number of biotech companies seeking pharmaceutical mergers. cc/t9s2jz 15-02-2020. Shire is certainly one of the best biotech stocks for 2016. Monsanto Targets Farmers, AFBF In Syngenta Takeover Posted by Matthew J. 86, recorded on April 10, 2019, and trades around $110. was an unexpected boost to the RNAi field. Start a 14-day free trial to Morningstar Premium to unlock our take on LXRX. Put an increasingly prevalent liver disease high on the list. Adam’s Take. 5 Promising Biotech Stocks That Could Be Takeover Targets March 29, 2019 by (in 2017), and expects to remain profitable from now on. And the returns can be staggering. by Investment U Research. I wouldn't buy the Eaton Vance fund. Now that the first quarter of 2020 has drawn to a close, the Investing News Network has rounded up the five best gold stocks on the TSXV with the biggest share price gains year-to-date. Takeovers are one of the fastest ways to strike it rich on Wall Street. Taking over the top spot for announced deal value for the quarter was Freshfields Bruckhaus Deringer, announcing $99. By Martin Baccardax. Published: 17:02 EDT, 11 January 2020. Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers. 8 Takeout targets to watch in 2018 Any company that can get its gene therapy technology to work will stand out as a takeover target. 7 'A'-Rated Stocks to Buy Under $10. to reflect the probability of being acquired by a large pharmaceutical company. Indiana virus cases top 11,200, state's death toll now 562 Big Pharma's hunt for new drugs pushes up cost of biotech deals. Acquisitions of Synthorx, ArQule, Audentes and Ra Pharmaceuticals came at premiums near or exceeding 100%, while Novartis' takeover of Medicines Co. Top Biotech Stocks for Q2 2020. January 14, 2020. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Brian Kelly, Chris Verrone and Steve Grasso. Oncolytics Biotech Inc. Shares Takeover Mergers and acquisitions Whitbread Morrisons BioMarin Pharmaceutical. Zacks Top 10 Stocks for 2020 In addition to the stocks discussed above, would you like to know about our 10 top tickers for the entirety of 2020? These 10 are painstakingly hand-picked from over. Here are five stocks that are attractive and most likely to be takeout targets in 2019. Biotech columnist Adam Feuerstein answers readers' questions about health care companies. The Zacks Consensus Estimate for the company's current-year earnings advanced 52. Cecelia Smith-Schoenwalder April 27, 2020 Texas Businesses to Reopen The stay-at-home order will expire and retail stores, restaurants, movie theaters and malls can reopen at 25% capacity on Friday. HTTP://tiny. 10, 2019 at 8:01 a. 4) InterMune, $1. Crispr's stock is likely to skyrocket and such a success would certainly put the company's name at the top of the buyout rumor stack. Five potential takeover targets: As foreign firms circle 'cheap' British businesses, ITV tops broker's New Year hit list. Industry watchers have been predicting for months that buyers would come for Biogen--and now, one report says, they have. January 16, 2020. Here Is His Top Pick. April 26, 2019; Crispr's stock is likely to skyrocket and such a success would certainly put the company's name at the top of the buyout rumor stack. " Neurocrine Biosciences. 4) InterMune, $1. for $73 a share in cash, or $5. HTTP://tiny. Learn about LXRX with our data and independent analysis including price, star rating, valuation, dividends, and financials. Departures Capital 591 views. 9 billion, made GEN’s 2016 Takeover Targets list. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Brian Kelly, Chris Verrone and Steve Grasso. Fighting US FOMO (Flirting With Models) U. Latest: 3 Stocks to Buy That Won Big From the Stimulus Package 5 Promising Biotech Stocks That Could Be Takeover Targets (in 2017), and expects to remain profitable from now on. Biotech Stocks Are Poised to Rise in 2020, Analyst Says. 86, recorded on April 10, 2019, and trades around $110. ) The expanded deal and complementary tech make Medigene a logical acquisition target for bluebird. Learn to Daytrade Breakout Momentum TradinIn the ever-changing world of biotech, major acquisitions are a frequent phenomenon. Alexion Pharmaceuticals, Inc. 2 COVID-19 Stocks for the 'New Normal' Workplace. This company has been in the takeover rumor mill for some time. Monsanto Targets Farmers, AFBF In Syngenta Takeover Posted by Matthew J. As part of a larger firm, they can carry less capital,. January 16, 2020. But of course, virtually every stock that makes a good takeover target, is a good investment too. Four years ago Endocyte was the laughing stock of biotech. 6 billion worth of deals in Q1 of 2020 compared to $35. Michael Yee, Jefferies analyst, discusses the next biotech breakout target. April 28, 2020 - This Chip Stock Pays a Nice Dividend, but Should You Buy? April 27, 2020 - Better Buy: Amazon vs. and Canada, which during January–June 2019 zoomed 35% year-over-year, to $293. Emerald Clinics puts medical cannabis ‘real world’ evidence in the spotlight with proposed ASX listing. 2 COVID-19 Stocks for the 'New Normal' Workplace. Biopharma management teams like to look busy during a time of crisis, plus bulking up helps prevent the loss of their jobs due to a takeover. Thursday, May 02, 2019. Jeff Reeves's Strength in Numbers Opinion: Three tech, three biotech companies that are top takeover targets in 2019 Published: Jan. In 2020, price-to-earnings valuations may expand to correct the market discount. Vertex Pharmaceuticals (NASDAQ: VRTX) has also experienced a surge, up 75% this year. 7 billion, per Market Data Forecast. The company has built a portfolio. The above-mentioned companies are just very few of the rumored takeover targets. Last year Sanofi and Genzyme bickered over a proposed takeover before Genzyme caved in, for more than $20 billion. Mineweb reported that Lundin Mining CEO Paul Conibear gave hints as to what the company was looking for in regards to copper and zinc mines. Insights and Biotech 2020 preview: Takeover targets, notable drug launches, and genome editing readouts. 7 Buyout Targets to Watch for in 2020 As prices fall, investors should keep an eye on these seven companies By Luke Lango , InvestorPlace Markets Analyst Mar 26, 2020, 10:53 am EDT March 26, 2020. None of these companies is a proverbial one-trick pony, and they all are potential takeover. ) The expanded deal and complementary tech make Medigene a logical acquisition target for bluebird. 4) InterMune, $1. PLC ADS AMRN Stock Message Board: AF's Biotech 2020 preview: Takeover targets, notable drug. Given the risk inherent in the sector it is important to pick stocks wisely- and choosing stocks recommended by top analysts is one way of pinpointing top biotech stocks. The pharmaceutical industry is under pressure. Six-month data from the open-label extension portion due 3Q 2020. went in the 2020 NFL Draft article/3-Biotech-Companies-Ripe-for. Fighting US FOMO (Flirting With Models) U. This Zacks Rank #1 company's expected earnings. 6 top international companies hiring in data right now 8 of the most innovative biotech start-ups in Europe right now Sale of IBD drug stands in the way of $63bn AbbVie takeover of. 981 million. All 3 were taken over in just 23 days, on average…and they delivered average profits of 78%. Top Picks 2020: Myovant Sciences Ltd. Zacks Top 10 Stocks for 2020 In addition to the stocks discussed above, would you like to know about our 10 top tickers for the entirety of 2020? These 10 are painstakingly hand-picked from over. Put an increasingly prevalent liver disease high on the list. Departures Capital 591 views. Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they've been right. Next Biotech Takeout Targets, NewLink Genetics Pulls 2020 Profit Guidance. Shares of Immunomedics rise 1% on FDA approval of breast-cancer drug MarketWatch. Bigger, more established biotech companies have been beaten down recently, but are likely to rebound. So, as you can see, opportunities abound. The company’s lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Last year Sanofi and Genzyme bickered over a proposed takeover before Genzyme caved in, for more than $20 billion. Morgan Healthcare. Indeed, one could go so far as to say that by buying any solid small- to mid-size drug stock, investors have a good chance that it will be taken over within the next 12 months. cancer firm insisting it was better off. Top 10 M&A targets in 2020 We have a look at the top potential takeover targets for 2020 and explain how investors and traders can capitalise. Geron Corporation (NASDAQ:GERN). Shares have been falling since 2017 on. Tulipmania has practically taken over the hepatitis C market, with Gilead Sciences. cancer firm insisting it was better off. 5 Top Drug/Biotech Merger & Acquisition Targets for 2019 - December 10, 2018 - Zacks. RockTalk is a new Stockhead video series featuring a roundtable of resources experts discussing a new topic each week. 1 billion in cash and a 62% premium to the company's market price — said it plans to spend more on its cancer-related research. Pound's post-Brexit plunge means more opportunistic deals are likely next year. Below, we'll take a look at the top 3 stocks in the biotechnology sector for the second quarter of 2020 in terms of the best value, the fastest earnings growth, and the most momentum. ( MYOV ) offers a new drug “pipeline in a pill”, asserts biotech expert Jay Silverman , contributing editor to Medical Technology Stock Letter. They are our primary picks to buy and hold. Alex­ion is al­so on every­one's top-5 list of takeover tar­gets. Top 34 Oil ETFs; Top 130 Commodity ETFs ETFs for the Next Biotech Takeover Targets. Adam's Take. 7 billion, per Market Data Forecast. Biotech got destroyed in Fall of 2018. (WPRI) - The manufacturing facility vacated last fall by Alexion Pharmaceuticals is getting a new owner. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Brian Kelly, Chris Verrone and Steve Grasso. Here are Mizuho's top nine biotech stocks to buy right now. 02:21 PM ET. cancer firm insisting it was better off. with mid- to late-stage gene therapy pipelines could be takeover targets. farmers, aiming to ease concerns about the proposed tie-up that could prompt regulatory challenges, reports. went in the 2020 NFL Draft article/3-Biotech-Companies-Ripe-for. Zacks Top 10 Stocks for 2020 In addition to the stocks discussed above, would you like to know about our 10 top tickers for the entirety of 2020? These 10 are painstakingly hand-picked from over. Wednesday, April 22, 2020. Trending; Sectors. Imugene granted HER-Vaxx immunotherapy patent in the United States. TipRanks analytics show that out of three analysts polled in the past 3 months, all three are bullish. Emerald Clinics puts medical cannabis ‘real world’ evidence in the spotlight with proposed ASX listing. It's hard to narrow it down, but we think these European biotechs are going to make headlines this year. LaCroix, a brand of canned sparkling water that comes in 15 flavors and has built up a fiercely loyal. Last year Sanofi and Genzyme bickered over a proposed takeover before Genzyme caved in, for more than $20 billion. With biotech stocks surging in the last part of 2019, next year is setting up to remain strong for the sector. Biogen (NASDAQ: BIIB) recently suffered a brutal stock market beating after its big Alzheimer's candidate failed to make a difference for patients with early signs of the disease. cc/t9s2jz HTTP://tiny. SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5. Gamida stock has a resounding “yes” on Wall Street. Why 4 Top Biotech Stocks May Be the Next Takeover Targets that mergers and acquisitions continue in the biotech space. PLC ADS AMRN Stock Message Board: AF's Biotech 2020 preview: Takeover targets, notable drug. Bret Jensen shares four more likely takeover targets that should be on your watchlist. Next Biotech Takeout Targets, NewLink Genetics Pulls 2020 Profit Guidance. The opinions expressed are his own. Citi Investment Research has upped price targets in the biotech sector, including Biogen Idec Inc. My 2 newest include: 2 Biotech Takeover Targets Under $7 and Forget Heart Disease: 1 Stock to Enjoy a Long, Healthy, Prosperous Retirement. 05 billion worth of merger-and-acquisition (M&A) deals in the biopharma industry. Jan 10, 2019 Three tech, three biotech companies that are top takeover targets in 2019 MarketWatch. 94% , AMGN, -3. Analyst Yaron Werber suggests Biogen is the most likely to be taken out, with a probability of 80 per cent. Phase 2 top-line data noted TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks - April 20, 2020. 6 billion worth of deals in Q1 of 2020 compared to $35. Meanwhile, the underlying forces creating demand for buyout targets remain. With biotech stocks surging in the last part of 2019, next year is setting up to remain strong for the sector. The stock is a buy under $17 with a target price of $25. The Nasdaq Biotech Index closed at a record last month and its price-sales ratio is at a decade high, data compiled by Bloomberg show. The outbreak of the novel coronavirus has heightened fears that hard-hit Swedish companies could be easy. Some analysts predict that the market for treatments of nonalcoholic steatohepatitis (NASH) could be between $20 billion and $35 billion. The article 3 Biotech Takeover Targets That Could Get Bought Soon originally appeared on Fool. The global blue biotech industry is set to soar 86% by 2024 and reach $6. Vascepa (icosapent ethyl) is a. 2 Top Biotech Takeover Targets. In each of its last two quarters, Alteryx has. A recent Mizuho investor survey pegged the company as one of the top four biotech's that the firm's investors. 5 billion francs. Taking over the top spot for announced deal value for the quarter was Freshfields Bruckhaus Deringer, announcing $99. Published: 17:02 EDT, 11 January 2020. Today, Valeant Pharmaceuticals kicked off its own hostile approach for Cephalon Inc. Six-month data from the open-label extension portion due 3Q 2020. Be a Bull in This Biotech Breakout. 9 billion francs by 2020, according to Reuters data, while just-introduced Uptravi sales could top 2. A Reuters analysis of 10 likely biotech takeover targets shows the extent to which a few large investors, including Fidelity Investments, Capital Research Global Investors, Wellington Management. Phase 2 top-line data noted TransCon PTH eliminated standard of care in 82 percent of subjects within four weeks - April 20, 2020. Takeover Targets: Anaconda Mining and two steps to success Peter Clausi | February 18, 2015 | 6 Comments Earlier in this series we looked at Integra Gold Corp, which became a takeover target when the market failed to price in meaningful information already in the public domain. Buy Target – $9. 81% and the SPDR S&P Biotech ETF XBI, -1. Biotech That Doubled on Covid-19 Frenzy Readies New Flu Vaccine By. Here are three top biotech stocks to watch in 2019. Nektar, BioMarin, and Alnylam top list of biotech M&A targets. struggles to convince rival Syngenta AG to discuss a potential merger , the seed and agrochemical giant is also wooing U. Competition for the takeover targets, however, has also meant. A roundup of STAT's top stories of the day in science and medicine. Gene therapy and oncology companies are targets. Tissue Regenix continues regeneration as it targets breaking even by 2020 Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11. Biogen is a biotech company that focuses on developing and discovering therapies that treat various diseases like autoimmune diseases and neurodegenerative problems. 3 Junior Gold Stocks Seen as Top Takeover Targets. 01:21 PM ET. Top 10 M&A targets in 2020 We have a look at the top potential takeover targets for 2020 and explain how investors and traders can capitalise. Departures Capital 591 views. Potential Suitors: Amazon, Walmart, eBay. Vascepa (icosapent ethyl) is a. A good buy for 2020. Biotech ended 2019 on a tear, buoyed by renewed dealmaking and unexpectedly positive trial results for several smaller companies. cc/t9s2jz HTTP://tiny. ” Seattle Genetics One is growing sales of its sole marketed drug Adcetris® (brentuximab vedotin) in the U. Top 10 M&A targets in 2020 We have a look at the top #potential takeover targets for 2020 and explain how investors and traders can capitalise. 981 million. The Nasdaq Biotech Index closed at a record last month and its price-sales ratio is at a decade high, data compiled by Bloomberg show. In each of its last two quarters, Alteryx has. Todd Campbell owns shares of PORTOLA PHARMACEUTICALS INC COM USD0. In fact, Genetic Engineering & Biotechnology News has had it on its takeover target list for six years now. However, one news outlet went on to report that one of the largest biotech stocks in the market is getting close to finalizing a major deal. Biotech CEOs Share Ideas for Coping With Coronavirus The Wall Street Journal 10:51 6-May-20 India to send nearly 1,000 tonnes of paracetamol raw material to Europe The Times of India 10:37 6-May-20 PCI Biotech: Notice of Annual General Meeting 2020 GlobeNewswire (Press Release) 10:07 6-May-20. Gene therapy and oncology companies are targets. Keep an eye out for Allergan, Arena Pharmaceuticals, and Bristol-Myers Squibb. Lundin Mining Scoping Out Potential Junior Zinc Takeover Targets Vivien Diniz - October 17th, 2012 Mineweb reported that Lundin Mining CEO Paul Conibear gave hints as to what the company was. Top Picks 2020: Myovant Sciences Ltd. The sales and profits of the pharmaceutical giants have been declining for years. 5 Top Drug/Biotech Merger & Acquisition Targets for 2019 - December 10, 2018 - Zacks. 2020 10:11 AM EDT. These 2 Biotechs Could Be The Next Big Takeover Targets. The company has a very robust pipeline, and steadily growing revenues. Jim Cramer's Top Takeover Targets for 2019 Trade tensions with China and a weaker economy could lead to a scarce M&A market in 2019, but tech, media and consumer deals could still trickle out. More biotech takeover targets coming:. The company is expected to report top-line data from tabelecleucel's late-stage trials within the first half of this year, which sets up a possible regulatory filing by mid-2020. Gilead's other two NASH drugs, GS-9674 and GS-0976, are in phase 2 clinical studies. Gilead Sciences also claims three pipeline candidates targeting NASH. When the market dropped in Q4 2018, Dylan Jovine recommended 3 small biotech's. 6 top international companies hiring in data right now 8 of the most innovative biotech start-ups in Europe right now Sale of IBD drug stands in the way of $63bn AbbVie takeover of. The FDA decision on Pemigatinib is expected by May 30, 2020. Bigger, more established biotech companies have been beaten down recently, but are likely to rebound. Biotech columnist Adam Feuerstein answers readers' questions about health care companies. A Biotech Takeover Target. went in the 2020 NFL Draft article/3-Biotech-Companies-Ripe-for. Taking over the top spot for announced deal value for the quarter was Freshfields Bruckhaus Deringer, announcing $99. Here are the top 5 takeover targets identified by Lone Pine Capital and snapped up by at least 38 hedge funds: Bonus Biotech Stock Pick: All text and design is copyright ©2020 Koala Guide. Make no mistake, biotech experiences booms and busts. Speculating on takeovers is a perennial entertainment for financial pundits of all stripes, since takeovers usually come at a nice hefty premium and often drive the target stock up by 30-50% or more in a single day, and we've seen several "takeover" focused newsletters pitched over the years… but it's a tough segment if you're counting on identifying a brand new takeover idea every. A Biotech Takeover Target. Biotech Stocks Are Poised to Rise in 2020, Analyst Says. Buy Target – $9. 4) InterMune, $1. These two takeout targets have what team Biogen’s looking for — plus there’s a good chance acquiring them could also work out well for Biogen’s shareholders down the line. struggles to convince rival Syngenta AG to discuss a potential merger , the seed and agrochemical giant is also wooing U. 18%, is up almost 14% over the past month. RockTalk is a new Stockhead video series featuring a roundtable of resources experts discussing a new topic each week. Support: 888 leading cause of liver transplants by 2020. ” Seattle Genetics One is growing sales of its sole marketed drug Adcetris® (brentuximab vedotin) in the U. Taking over the top spot for announced deal value for the quarter was Freshfields Bruckhaus Deringer, announcing $99. Rumors don't always pan out, and when that happens, the stocks could suffer. 8 billion, both in January. INCY has gained 43% year-to-date and trades around $91. Nektar, BioMarin, and Alnylam top list of biotech M&A targets. Indeed, one could go so far as to say that by buying any solid small- to mid-size drug stock, investors have a good chance that it will be taken over within the next 12 months. The highly specialised state-of-the-art facilities for oncology drugs and injectables in India have been the targets of MNCs. 86, recorded on April 10, 2019, and trades around $110.